BridgeBio Pharma, Inc.
HealthcareNASDAQ:BBIO · NASDAQ Global Select
-$0.75 today
Vol 1.47M · Avg 2.47M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $879.9M |
| Short-term Investments | $60.3M |
| Receivables | $205.2M |
| Inventory | $33.0M |
| Total Current Assets | $1.2B |
| PP&E (Net) | $22.2M |
| Intangible Assets | $27.4M |
| Long-term Investments | $63.1M |
| Other Non-current | -$63.1M |
| Total Non-current Assets | $49.5M |
| Total Assets | $1.4B |
Analysis
Selected assets total $1.4B for Latest. The largest visible component is Cash & Equivalents at $879.9M, about 64.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $570.1M -16.3% | $681.1M +81.2% | $375.9M -0.2% | $376.7M -4.3% | $393.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $17.4M | $0 -100.0% | $58.9M -38.1% | $95.2M -78.5% | $442.9M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $139.4M +2853.1% | $4.7M +169.7% | $1.8M -89.7% | $17.1M -13.5% | $19.7M | $533.8M | $399.4M | -$1.7B |
| Inventory | $26.8M | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $0 -100.0% | $3.8M -86.2% | $27.7M -27.1% | $37.9M +21329.4% | $177.0K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $753.7M +4.6% | $720.7M +50.9% | $477.6M -13.0% | $548.9M -38.3% | $888.9M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $13.5M +5.8% | $12.8M -35.6% | $19.8M -21.4% | $25.2M -45.1% | $46.0M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $28.1M +17.3% | $23.9M -9.1% | $26.3M -8.3% | $28.7M -36.1% | $44.9M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $81.4M -43.3% | $143.7M | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | -$81.4M -547.6% | $18.2M -19.6% | $22.6M +11.9% | $20.2M -38.8% | $33.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $41.6M -79.1% | $198.6M +188.8% | $68.8M -7.3% | $74.2M -40.1% | $123.9M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $936.0M +1.8% | $919.3M +68.3% | $546.4M -12.3% | $623.0M -38.5% | $1.0B | $13.3B | $11.9B | $10.6B |
| Account Payables | $36.2M +276.7% | $9.6M -9.7% | $10.7M -7.8% | $11.6M -2.7% | $11.9M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $17.4M | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $20.3M | $0 -100.0% | $6.1M -25.3% | $8.2M | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $214.1M +1221.4% | $16.2M -75.3% | $65.6M +109.9% | $31.3M -15.6% | $37.0M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $288.0M +86.5% | $154.4M +7.3% | $143.8M +18.5% | $121.4M -10.1% | $135.1M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $2.7B +57.3% | $1.7B -0.3% | $1.7B +1.1% | $1.7B +0.2% | $1.7B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $13.1M | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $244.0K -100.0% | $496.5M +5203.6% | $9.4M -64.9% | $26.6M +20.7% | $22.1M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $2.7B +22.6% | $2.2B +27.4% | $1.7B -0.1% | $1.7B +0.2% | $1.7B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $3.0B +26.7% | $2.4B +25.8% | $1.9B +1.1% | $1.9B -0.6% | $1.9B | $14.7B | $3.7B | $9.6B |
| Common Stock | $202.0K +3.1% | $196.0K +8.3% | $181.0K +15.3% | $157.0K +1.9% | $154.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$3.8B -23.4% | -$3.1B -20.9% | -$2.6B -33.5% | -$1.9B -33.5% | -$1.4B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $12.0K +50.0% | $8.0K -74.2% | $31.0K +109.5% | -$328.0K -148.5% | -$132.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | -$570.0K -105.5% | $10.3M -12.2% | $11.7M +20.9% | $9.7M +100.5% | $4.8M | $1.4B | $337.8M | $931.4M |
| Total Equity | -$2.1B -42.5% | -$1.5B -8.6% | -$1.3B -7.8% | -$1.2B -43.8% | -$865.6M | $9.1B | $7.7B | $3.3B |
| Total Debt | $2.7B +57.7% | $1.7B -0.5% | $1.7B +0.9% | $1.7B -0.2% | $1.7B | $724.2M | $410.6M | $399.4M |
| Net Debt | $2.2B +105.7% | $1.0B -23.1% | $1.4B +1.3% | $1.3B +1.1% | $1.3B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.71B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.61B
Moderna, Inc.
NASDAQ:MRNA
$19.80B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.48B
Ascendis Pharma A/S
NASDAQ:ASND
$13.47B
Exelixis, Inc.
NASDAQ:EXEL
$13.35B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.11B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.86B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.81B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does BBIO have?
BridgeBio Pharma, Inc. (BBIO) reported $570.12M in cash and equivalents in fiscal 2025.
How much debt does BBIO carry?
BridgeBio Pharma, Inc. (BBIO) reported $2.73B of total debt, with net debt of $2.16B.
Explore More
Continue the stock analysis
Jump to another research area for this company.